What exactly changed in the Feb 26, 2026 Leerink note on GDRX analyst rating?

Leerink maintained an **Outperform** rating on **Feb 26, 2026** but cut the price target from **$6** to **$3**. The note cited weaker guidance and slower near-term monetization as the drivers of the PT reduction.

How should investors interpret a maintained Outperform with a lower price target?

A maintained Outperform with a lower PT means the analyst still prefers the stock over peers but sees near-term pressure. Investors should weigh the reduced near-term forecast against possible long-term recovery.

Did the GDRX analyst rating move affect the stock price immediately?

Yes. The note corresponded with a reported **17.33% ($0.35)** move from the referenced level. Lowered targets often prompt short-term selling even when the rating remains constructive.

What is Meyka’s view after the Leerink action on GDRX analyst rating?

Meyka AI assigns GDRX a **B+** grade, reflecting mixed near-term risk and decent longer-term prospects. We emphasize monitoring earnings, guidance, and subscriber metrics before increasing exposure.

Analyst Ratings

Leerink Maintains Outperform on GoodRx (GDRX) Feb 26, 2026 PT $3

ByDanny Kontos February 27, 2026

On February 26, 2026 at 01:08 PM, Leerink Partners maintained an Outperform rating on GoodRx Holdings, Inc. (GDRX) while lowering its price target to $3. This GDRX analyst rating update followed management’s weak guidance and trims investor expectations. The StreetInsider note and related Investing.com coverage flagged the PT cut from $6 to $3. The move ties to recent earnings details and pushed the stock down; the reported price change since the note was 17.33% ($0.35). We assess what the maintained rating and lower target mean for investors.